Thrivent Financial for Lutherans Has $20.25 Million Position in argenx SE (NASDAQ:ARGX)

Thrivent Financial for Lutherans boosted its position in shares of argenx SE (NASDAQ:ARGX) by 1.5% during the 3rd quarter, HoldingsChannel reports. The fund owned 37,352 shares of the company’s stock after buying an additional 564 shares during the quarter. Thrivent Financial for Lutherans’ holdings in argenx were worth $20,248,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in the company. Blue Trust Inc. lifted its holdings in shares of argenx by 620.0% during the 2nd quarter. Blue Trust Inc. now owns 72 shares of the company’s stock worth $28,000 after acquiring an additional 62 shares during the period. J.Safra Asset Management Corp increased its stake in argenx by 590.0% in the second quarter. J.Safra Asset Management Corp now owns 69 shares of the company’s stock valued at $30,000 after acquiring an additional 59 shares during the period. GAMMA Investing LLC raised its position in argenx by 51.3% in the second quarter. GAMMA Investing LLC now owns 118 shares of the company’s stock worth $51,000 after purchasing an additional 40 shares in the last quarter. Point72 Hong Kong Ltd bought a new position in argenx during the second quarter worth about $76,000. Finally, Cromwell Holdings LLC lifted its stake in argenx by 73.3% during the third quarter. Cromwell Holdings LLC now owns 156 shares of the company’s stock worth $85,000 after purchasing an additional 66 shares during the period. Institutional investors and hedge funds own 60.32% of the company’s stock.

argenx Trading Up 3.0 %

Shares of NASDAQ ARGX opened at $591.82 on Thursday. The firm has a market capitalization of $35.39 billion, a PE ratio of -672.52 and a beta of 0.61. The firm’s 50-day moving average is $555.08 and its 200-day moving average is $485.94. argenx SE has a 1 year low of $327.73 and a 1 year high of $611.22.

argenx (NASDAQ:ARGX) last released its earnings results on Thursday, October 31st. The company reported $1.39 EPS for the quarter, topping analysts’ consensus estimates of $0.10 by $1.29. The firm had revenue of $588.88 million during the quarter, compared to analyst estimates of $543.29 million. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. During the same quarter in the previous year, the business earned ($1.25) EPS. As a group, equities research analysts anticipate that argenx SE will post 2.2 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on ARGX. Robert W. Baird cut argenx from an “outperform” rating to a “neutral” rating and increased their target price for the stock from $515.00 to $650.00 in a report on Friday, November 1st. Scotiabank raised argenx from a “sector perform” rating to a “sector outperform” rating and lifted their price objective for the company from $439.00 to $715.00 in a report on Tuesday, November 5th. Raymond James restated a “strong-buy” rating and issued a $605.00 target price on shares of argenx in a research note on Thursday, October 10th. Wedbush increased their target price on shares of argenx from $519.00 to $560.00 and gave the stock an “outperform” rating in a research report on Friday, July 26th. Finally, Baird R W lowered shares of argenx from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 1st. Three equities research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $619.79.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.